These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 17073727)
1. In silico criterion for prediction of effects of p53 gene missense mutations on p53-Mdm2 feedback loop. Veljkovic N; Perovic V Protein Pept Lett; 2006; 13(8):807-14. PubMed ID: 17073727 [TBL] [Abstract][Full Text] [Related]
2. MDM2-p53 pathway in hepatocellular carcinoma. Meng X; Franklin DA; Dong J; Zhang Y Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334 [TBL] [Abstract][Full Text] [Related]
3. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594 [TBL] [Abstract][Full Text] [Related]
4. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952 [TBL] [Abstract][Full Text] [Related]
5. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689 [TBL] [Abstract][Full Text] [Related]
6. On p53 revival using system oriented drug dosage design. Haseeb M; Azam S; Bhatti AI; Azam R; Ullah M; Fazal S J Theor Biol; 2017 Feb; 415():53-57. PubMed ID: 27979498 [TBL] [Abstract][Full Text] [Related]
9. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Gajjar M; Candeias MM; Malbert-Colas L; Mazars A; Fujita J; Olivares-Illana V; Fåhraeus R Cancer Cell; 2012 Jan; 21(1):25-35. PubMed ID: 22264786 [TBL] [Abstract][Full Text] [Related]
10. The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noise. Puszynski K; Gandolfi A; d'Onofrio A PLoS Comput Biol; 2014 Dec; 10(12):e1003991. PubMed ID: 25504419 [TBL] [Abstract][Full Text] [Related]
11. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis. Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028 [TBL] [Abstract][Full Text] [Related]
12. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Okamoto K; Kashima K; Pereg Y; Ishida M; Yamazaki S; Nota A; Teunisse A; Migliorini D; Kitabayashi I; Marine JC; Prives C; Shiloh Y; Jochemsen AG; Taya Y Mol Cell Biol; 2005 Nov; 25(21):9608-20. PubMed ID: 16227609 [TBL] [Abstract][Full Text] [Related]
13. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Gupta A; Shah K; Oza MJ; Behl T Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517 [TBL] [Abstract][Full Text] [Related]
14. Acidic domain is indispensable for MDM2 to negatively regulate the acetylation of p53. Wang Q; Yang Y; Wang L; Zhang PZ; Yu L Biochem Biophys Res Commun; 2008 Sep; 374(3):437-41. PubMed ID: 18638452 [TBL] [Abstract][Full Text] [Related]
15. Dysfunction of the MDM2/p53 axis is linked to premature aging. Lessel D; Wu D; Trujillo C; Ramezani T; Lessel I; Alwasiyah MK; Saha B; Hisama FM; Rading K; Goebel I; Schütz P; Speit G; Högel J; Thiele H; Nürnberg G; Nürnberg P; Hammerschmidt M; Zhu Y; Tong DR; Katz C; Martin GM; Oshima J; Prives C; Kubisch C J Clin Invest; 2017 Oct; 127(10):3598-3608. PubMed ID: 28846075 [TBL] [Abstract][Full Text] [Related]
16. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559 [TBL] [Abstract][Full Text] [Related]
17. Mdm2-mediated ubiquitylation: p53 and beyond. Marine JC; Lozano G Cell Death Differ; 2010 Jan; 17(1):93-102. PubMed ID: 19498444 [TBL] [Abstract][Full Text] [Related]
18. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop. Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750 [TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of the p53-Mdm2 feedback loop using protein lysate microarrays. Ramalingam S; Honkanen P; Young L; Shimura T; Austin J; Steeg PS; Nishizuka S Cancer Res; 2007 Jul; 67(13):6247-52. PubMed ID: 17616682 [TBL] [Abstract][Full Text] [Related]
20. Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Shimizu H; Saliba D; Wallace M; Finlan L; Langridge-Smith PR; Hupp TR Biochem J; 2006 Jul; 397(2):355-67. PubMed ID: 16579792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]